

### **JW Modifier**



Drug amount discarded/not administered to any patient

CDR Malluwa-Wadu, Prabath, PharmD Laura Kennedy, PharmD, BCPS

## **Disclaimer Statement**

I Prabath Malluwa-Wadu, CMS employee, declare no conflicts of interest or financial interests in any product or service mentioned in this program, including grants, employment, gifts, stock holdings, or honoraria.

## **Outline**

- Policy History
- 2017 and 2018 data
- Examples of savings with small dose vials
- From the Manual
- Limitations of JW Modifier
- Downloads

## **Policy History**

- JW Modifier created in January 01, 2003
- Optional until January 01, 2017
  - CMS issued a CR on June 9, 2016 (Transmittal#: R3538CP)
  - MLN Matters Article #: MM9603 issued on June 10, 2016
  - CMS published a FAQ on August 26, 2016
  - Effective date adjusted to January 1, 2017 to
     accommodate implementation concerns from providers

### **Discarded Drug Units Report**

#### 2017

| Total Allowed Amount | Total Allowed Amount for Units Administered | Total Allowed<br>Amount for Units<br>Discarded | Administered Units as<br>% of Total Allowed<br>Amount | Discarded Units as % of Total Allowed Amount |
|----------------------|---|--|---|--|
| \$31,824,074,997     | \$31,128,625,599                            | \$695,449,398                                  | 97.8%   | 2.2%   |

#### 2018

|                      | Total Allowed           | Total Allowed    | Administered Units as | Discarded Units as % |  |
|----------------------|-------------------------|------------------|-----------------------|----------------------|--|
| Total Allowed Amount | <b>Amount for Units</b> | Amount for Units | % of Total Allowed    | of Total Allowed     |  |
|                      | Administered            | Discarded        | Amount                | Amount               |  |
| \$34,756,260,823     | \$34,030,984,960        | \$725,275,863    | 97.9%                 | 2.1%                 |  |

### **Drug Codes with >10% Wasted**

| HCPCS Code | Brand Name       | Generic Name                  | # of Vial Sizes | Weight<br>Based Dose? | MS or SS | Single Use Vials<br>Only? | 2018 Discarded<br>Units as % of<br>Total Allowed<br>Amount |
|------------|------------------|-------------------------------|-----------------|-----------------------|----------|---------------------------|--|
| J9041      | Velcade          | Bortezomib                    | 1               | Υ                     | SS       | Υ                         | 26.48%   |
| J9043      | Jevtana          | Cabazitaxel                   | 1               | Υ                     | SS       | Υ                         | 26.24%   |
| J9351      | Hycamtin (J9351) | Topotecan HCL                 | 1               | Υ                     | MS       | Υ                         | 23.39%   |
| J0894      | Dacogen          | Decitabine                    | 1               | Υ                     | MS       | Υ                         | 22.52%   |
| J9025      | Azacitidine      | Azacitidine                   | 1               | Υ                     | MS       | Υ                         | 22.13%   |
| J2796      | NPlate           | Romiplostim                   | 1               | Υ                     | SS       | Υ                         | 21.61%   |
| J9017      | Trisenox         | ArsenicTrioxide               | 2               | Υ                     | MS       | Υ                         | 17.81%   |
| J9100      | Cytarabine       | Cytarabine                    | 4               | Υ                     | MS       | N                         | 16.46%   |
| J1640      | Panhematin       | Hemin                         | 1               | Υ                     | SS       | Υ                         | 15.90%   |
| J0775      | Xiaflex          | Collagenase Clostridium Hist. | 1               | N                     | SS       | Υ                         | 15.79%   |
| J9065      | Cladribine       | Cladribine                    | 1               | Υ                     | MS       | Υ                         | 15.63%   |
| J3300      | Triesence        | Triamcinolone Acetonide/PF    | 1               | N                     | SS       | Υ                         | 14.16%   |
| J9264      | Abraxane         | Paclitaxel Protein-Bound      | 1               | Υ                     | SS       | Υ                         | 13.68%   |
| Q9950      | Lumason          | Sulfur Hexafluoride Microsphr | 1               | N                     | SS       | Υ                         | 13.12%   |
| J1451      | Fomepizole       | Fomepizole                    | 1               | Υ                     | MS       | Υ                         | 12.72%   |
| J9047      | Kyprolis         | Carfilzomib                   | 3               | Υ                     | SS       | Υ                         | 12.68%   |
| J9307      | Folotyn          | Pralatrexate                  | 2               | Υ                     | SS       | Υ                         | 12.66%   |
| J9178      | Ellence          | Epirubicin HCL                | 2               | Υ                     | MS       | Υ                         | 12.20%   |
| J9179      | Halaven          | Eribulin Mesylate             | 1               | Υ                     | SS       | Υ                         | 11.63%   |
| J9042      | Adcetris         | Brentuximab Vedotin           | 1               | Υ                     | SS       | Υ                         | 10.61%   |
| J9328      | Temodar (J9328)  | Temozolomide                  | 1               | Υ                     | SS       | Υ                         | 10.40%   |
| J9315      | Istodax          | Romidepsin                    | 1               | Υ                     | MS       | Υ                         | 10.37%   |
| J0485      | Nulojix          | Belatacept                    | 1               | Υ                     | SS       | Υ                         | 10.23%   |
| J9205      | Onivyde          | Irinotecan Liposomal          | 1               | Υ                     | SS       | Υ                         | 10.22%   |
| J2562      | Mozobil          | Plerixafor                    | 1               | Υ                     | SS       | Υ                         | 10.21%   |

### > 10% Wasted Drug Codes

- 19/25 one vial size
- 23/25 weight based dose
- 16/25 single source
- 24/25 single use vials only
- 19/25 in 2017 (25/25 in 2018)

# 2017 Top 10 Most Costly Waste

| HCPCS<br>Code | Brand Name  | Generic Name                      | # of<br>Vial<br>Sizes | Weight<br>Based Dose? | Single or<br>Multi Source | Single<br>Use Vials<br>only? | Total Allowed<br>Amount | Total Allowed<br>Amount for<br>Units Discarded | Discarded<br>Units as % of<br>Total<br>Allowed<br>Amount |
|---------------|-------------|-----------------------------------|-----------------------|-----------------------|---------------------------|------------------------------|-------------------------|--|--|
| J9041         | Velcade     | Bortezomib                        | 1                     | Υ                     | SS                        | Υ                            | \$504,941,847.93        | \$127,794,525.29                               | 25.31%   |
| J2796         | NPlate      | Romiplostim                       | 1                     | Υ                     | SS                        | Υ                            | \$217,979,614.95        | \$45,487,770.55                                | 20.87%   |
| J9271         | Keytruda    | Pembrolizumab Paclitaxel Protein- | 1                     | N                     | SS                        | Υ                            | \$1,059,618,867.13      | \$42,302,805.32                                | 3.99%  |
| J9264         | Abraxane    | Bound                             | 1                     | Υ                     | SS                        | Υ                            | \$277,344,459.04        | \$37,884,531.39                                | 13.66%   |
| J9047         | Kyprolis    | Carfilzomib                       | 3                     | Υ                     | SS                        | Υ                            | \$262,887,883.87        | \$37,504,762.85                                | 14.27%   |
| J9035         | Avastin     | Bevacizumab                       | 2                     | Υ                     | SS                        | Υ                            | \$1,097,318,498.44      | \$34,232,714.32                                | 3.12%  |
| J9355         | Herceptin   | Trastuzumab                       | 2                     | Υ                     | SS                        | N                            | \$811,808,411.14        | \$34,156,754.38                                | 4.21%  |
| J2357         | Xolair      | Omalizumab                        | 2                     | Υ                     | SS                        | Υ                            | \$394,891,920.98        | \$23,873,681.87                                | 6.05%  |
| J0585         | Botox       | Onabotulinumtoxina                | 3                     | Υ                     | SS                        | Υ                            | \$329,599,269.89        | \$22,864,539.07                                | 6.94%  |
| J9025         | Azacitidine | Azacitidine                       | 1                     | Υ                     | MS                        | Υ                            | \$96,036,435.49         | \$20,813,879.26                                | 21.67%   |

Accounts for 61.4% of total allowed amount for units discarded

# 2018 Top 10 Most Costly Waste

| HCPCS<br>Code | Brand Name   | Generic Name                    | # of<br>Vial<br>Sizes | Weight<br>Based Dose? | Single or<br>Multi Source | Single<br>Use Vials<br>only? | Total Allowed<br>Amount | Total Allowed<br>Amount for<br>Units Discarded | Discarded<br>Units as % of<br>Total<br>Allowed<br>Amount |
|---------------|--------------|---------------------------------|-----------------------|-----------------------|---------------------------|------------------------------|-------------------------|--|--|
| J9041         | Velcade      | Bortezomib                      | 1                     | Υ                     | SS                        | Υ                            | \$462,999,930.98        | \$122,588,404.06                               | 26.48%   |
| J9355         | Herceptin    | Trastuzumab                     | 2                     | Υ                     | SS                        | N                            | \$851,399,897.40        | \$77,731,188.55                                | 9.13%  |
| J2796         | NPlate       | Romiplostim Paclitaxel Protein- | 1                     | Υ                     | SS                        | Υ                            | \$225,939,265.97        | \$48,815,556.29                                | 21.61%   |
| J9264         | Abraxane     | Bound                           | 1                     | Υ                     | SS                        | Υ                            | \$277,483,898.42        | \$37,950,268.03                                | 13.68%   |
| J9047         | Kyprolis     | Carfilzomib                     | 3                     | Υ                     | SS                        | Υ                            | \$259,705,122.69        | \$32,925,500.14                                | 12.68%   |
| J9035         | Avastin      | Bevacizumab                     | 2                     | Υ                     | SS                        | Υ                            | \$1,043,604,599.80      | \$32,469,356.10                                | 3.11%  |
| J0585         | Botox        | Onabotulinumtoxina              | 3                     | N                     | SS                        | Υ                            | \$353,367,190.48        | \$27,666,069.90                                | 7.83%  |
| J9043         | Jevtana      | Cabazitaxel                     | 1                     | Υ                     | SS                        | Υ                            | \$100,444,301.50        | \$26,358,823.67                                | 26.24%   |
| J2357         | Xolair       | Omalizumab                      | 2                     | Υ                     | SS                        | Υ                            | \$411,342,516.57        | \$26,037,522.19                                | 6.33%  |
| J1602         | Simponi Aria | Golimumab                       | 1                     | Υ                     | SS                        | Υ                            | \$304,266,077.97        | \$23,186,626.73                                | 7.62%  |

Accounts for **62.8**% of total allowed amount for units discarded

#### J9041

• Usual dose: 1.3 kg/m<sup>2</sup>

• Available vial size: 3.5 mg

| Weight-<br>based dose | Dose for 1.7<br>m² patient | Vial size | Waste   | Percent<br>waste |
|-----------------------|----------------------------|-----------|---------|------------------|
| 1.3 mg/m²             | 2.21 mg                    | 3.5 mg    | 1.29 mg | 36%              |

Patient weight/BSA to utilize entire vial: ~300kg or 2.69 m<sup>2</sup>

#### J9047

- Usual dose: 20—70 kg/m²
- Available vial sizes: 10 mg, 30 mg, 60 mg
- 10 mg vial became available 3Q18

| Weight-<br>based dose | Dose for 1.7<br>m² patient | Possiblevial size combinations | Waste | Percent<br>waste |
|-----------------------|----------------------------|--------------------------------|-------|------------------|
| 20 mg/m²              | 24 mg                      | 60 mg                          | 26 mg | 43.3%            |
| 20 mg/m <sup>2</sup>  | 34 mg                      | 30 mg + 10 mg                  | 6 mg  | 15%              |
| 27 mg/m²              | 46 mg                      | 60 mg                          |       | 23.3%            |
|                       | 46 mg                      | 30 mg + (2) 10 mg              | 4 mg  | 8%               |
| =6 mg/m²              | 0 <b>=</b> m a             | (2) 60 mg                      | 25 mg | 20.8%            |
| 56 mg/m <sup>2</sup>  | 95 mg                      | 60 mg + 30 mg + 10 mg          | 5 mg  | 5%               |
| 70 mg/m²              | 119 mg                     | (2) 60 mg                      | ı mg  | 0.8%             |

## From the Manual

- Medicare provides payment for the amount of drug or biological discarded as well as the dose administered, up to the amount of the drug or biological as indicated on the vial or package label
  - Medicare does not pay for overfill
- Unused drugs or biologicals from single use vials or single use packages
  - Not multiple dose vials or packages
- JW modifier is not permitted when the actual dose of the drug or biological administered is less than the billing unit
  - Part B drugs are not billable in fractions of HCPCS or other billing units
  - Providers must record the discarded amounts of drugs and biologicals in the patient's medical record
    - Provider burden

## **Limitations**

- The modifier is not required if no discarded drug is being billed to any payer
- Used mostly in the physician's office and hospital outpatient settings
  - drugs used incident to physicians' services
- May not be required in a hospital pharmacy
  - it may not be possible to quantify discarded quantities of drugs and associate them with a beneficiary, particularly with batch preparation
- Not required in a Rural Health Clinic (RHC) or a Federally Qualified Health Center (FQHC)
  - Drugs and biologicals are generally not separately payable under Part B
- Not intended for use under the Inpatient Prospective Payment System

## Limitations

- The modifier is not required in packaged OPPS drugs
- Not used when the actual dose administered is less than the HCPCS billing unit
  - also not required if the amount of drug that is discarded is less that the
     amount described by one HCPCS billing unit
- Not required when the quantity of discarded drug cannot be quantified

JW Modifier is a Medicare Part B policy. CMS has no information regarding how other insurance programs are tracking/paying for wasted drugs.

## **Downloads**

- CMS FAQ:
  - https://www.cms.gov/Medicare/Medicare-Fee-for-Service Payment/HospitalOutpatientPPS/Downloads/JW-Modifier-FAQs.pdf
- MLN Matters # MM9603:
  - https://www.cms.gov/Outreach-and-Education/Medicare-Learning-Network-MLN/MLNMattersArticles/Downloads/MM9603.pdf
- CMS CR Transmittal 3538:
  - https://www.cms.gov/Regulations-and Guidance/Guidance/Transmittals/Downloads/R3538CP.pdf
- Medicare Claims Processing Manual, Chapter 17 Drugs and Biologicals:
  - https://www.cms.gov/Regulations-and Guidance/Guidance/Manuals/downloads/clm104c17.pdf
- Medicare Part B Discarded Drug Units Report:
  - https://www.cms.gov/research-statistics-data-systems/cms-drugspending/medicare-part-b-discarded-drug-units-report

# Thank you

Questions?